Trial go-ahead for heart attack imaging agent:
This article was originally published in Clinica
Canada's Draximage has received permission from both the US FDA and the Canadian Therapeutic Products Programme to begin a Phase I clinical trial of its imaging agent for the early detection of heart attack. Amiscan, a technetium-99m labelled derivative of D-glucaric acid, will be assessed in 10 patients in a study conducted by Dr Raymond Taillefer of the Centre Hospitalier de L'Universite de Montreal - Hotel Dieu Campus. Draximage, a subsidiary of Draxis Health, is based in Kirkland, Quebec.